You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Developing a clinical diagnostic tool for age-related cochlear synaptopathy.

    SBC: GATEWAY BIOTECHNOLOGY, INC.            Topic: NIA

    Age-related hearing loss (ARHL) is the predominant neurodegenerative disease of aging. Recent animal studies have demonstrated that the earliest cochlear pathology due to noise and aging involves a loss of the inner hair cell ribbon synapse. The early consequences of this synaptic loss are not believed to affect hearing sensitivity, but rather, impair speech understanding in background noise. Whil ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Development and Commercialization of a New Molecularly Targeted Imaging Agent for Multiple Myeloma

    SBC: Sarya, LLC            Topic: 102

    PROJECT SUMMARY Sarya LLC (Sarya) is a nuclear medicine technology company formed to commercialize radiopharmaceuticals. The goal of this Fast-Track STTR is to develop a new specific imaging agent for diagnosis, staging, and treatment of the hematological cancer, multiple myeloma (MM). MM is the 2nd most common blood cancer with an estimated 32,000 new cases and 13,000 deaths per year. Accurate de ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. An Interactive Education Program to Reduce High Risk Behavior in Adolescents

    SBC: KLEIN BUENDEL, INC.            Topic: NICHD

    Internet-based TRAC (i-TRAC): Interactive Emotion Regulation Skills Training to Improve AdolescentSexual Health Adolescence is a critical developmental period during which behavioral patterns are formed that have powerful influences on current and future health. This is particularly true for sexual behavior, which is affected by the biological changes of puberty as well as normative developmental ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. CCR4-IL2 Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-Cell Lymphoma

    SBC: ROCK IMMUNE LLC            Topic: 102

    Abstract Cutaneous T-cell lymphoma (CTCL) is a type of extra-nodal non-Hodgkin’s lymphoma characterized by skinlesions resulting from infiltration of malignant T lymphocytes. Mycosis fungoides and Sezary syndrome are thetwo most common types of CTCL. Although treatments exist, they are mainly palliative with low response anddurability of response without any cure. The objective response rate rem ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Mitofusin Agonists to Treat Neurodegenerative Disease

    SBC: Mitochondria in Motion, Inc.            Topic: 104

    Mitofusin agonists for the treatment of neurodegenerative diseases Gerald W Dorn II, MD Mitochondria in Motion, Inc. Washington University in St Louis School of Medicine Abstract: A number of rare neurodegenerative diseases are characterized by mitochondrial fragmentation, dysmotility and dysfunction. Among these are Amyotrophic Lateral Sclerosis (ALS) and Huntington’s Disease (HD), which cause ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  6. Translating an In-Person Brief, Bystander Bullying Intervention (STAC) to a Technology-Based- Phase II

    SBC: KLEIN BUENDEL, INC.            Topic: 102

    While studies support the efficacy of comprehensive, school-wide interventions in reducing bullying, these types of programs can require significant time and financial resources for implementation, resulting in barriers to providing school-based bullying prevention, especially in low-income and rural communities. Additionally, although training bystanders to act as “defenders” on behalf of tar ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Novel tetrahedron beam CT for point-of-care imaging in ear, nose and throat imaging

    SBC: TETRAIMAGING LLC            Topic: NIBIB

    ABSTRACT Point-of-care imaging is highly desired in otolaryngologic clinics for the diagnosis of ear, nose and throat (ENT) diseases including cancers. Due to limited image quality, current cone-beam CT (CBCT) products act not as a substitute but rather as a complement to diagnostic Multi-slice CT (MSCT) in maxillofacial and ENT imaging. The emerging multi-source x-ray source technology suggests n ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Smartphone App to Increase and Maintain Physical Activity in African American Men (FitBrothers)

    SBC: KLEIN BUENDEL, INC.            Topic: 102

    Physical activity (PA) is a modifiable risk factor for a number of preventable chronic diseases, including cardiovascular disease, strokes, obesity, and diabetes. These conditions constitute health disparities for African American men. Behavioral interventions have proven to be effective in promoting increases in physical activity. While behavior change programs have been shown to assist participa ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Preclinical Development of ACXT-3102 for the Treatment of Pancreatic Adenocarcinoma (PDAC)

    SBC: Accuronix Therapeutics Inc            Topic: 102

    Project Summary/Abstract Pancreatic cancer is a devastating disease with a very low (8%) 5-year survival rate. Therapeutic options are limited in efficacy and many have substantial toxicity. Targeted drug delivery may improve the therapeutic index of cancer drugs by enhancing drug localization to the cancer cell while minimizing off-target side effects. Sigma-2 receptors (S2R) are highly expressed ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  10. Mitofusin agonists to prevent Charcot-Marie-Tooth disease 2A

    SBC: Mitochondria in Motion, Inc.            Topic: NINDS

    Mitofusin agonists to prevent Charcot-Marie-Tooth disease 2A Gerald W Dorn II, MD Mitochondria in Motion, Inc. Washington University in St Louis School of Medicine Abstract: Charcot-Marie-Tooth (CMT) disease type 2A is an incurable, primarily pediatric, autosomal dominant neuromuscular degenerative disease caused by mutations in the mitofusin (MFN) 2 gene. There are currently no disease-altering t ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government